Commandez votre montre hebdomadaire Deciphera Pharmaceuticals, LLC
Quantité totale PI	227
Rang # Quantité totale PI	5 826
Note d'activité PI	3,2/5.0    231
Rang # Activité PI	2 982
Classe Nice dominante	Produits pharmaceutiques, vétéri...

Brevets Marques 93 16 26 9 67 3 13
Dernier brevet	2025 - Processes of making csf-1r inhib...
Premier brevet	2003 - Anti-cancer medicaments
Dernière marque	2025 - QINLOCK
Première marque	2019 - QINLOCK

Industrie (Classification de Nice)

Derniers inventions, produits et services 2025 P/S Pharmaceutical oncology treatments, namely, preparations for gastrointestinal stromal tumors, sy... P/S downloadable mobile application for use by patients to manage, track, and generate reports on med... P/S Provision of consumer information for healthcare providers and patients regarding prescription me... Invention Processes of making csf-1r inhibitors and methods of use thereof. The present disclosure relates ... Invention Csf-1r inhibitors and methods of use thereof. Provided herein, in part, is a compound of Formula ... Invention Methods of treating disorders using csf1r inhibitors. Described herein are methods of treating c... Invention Solid state forms of a kinase inhibitor. Described herein, in part, are solid-state forms of the... Invention Formulations of vimseltinib. Described herein, in part, are pharmaceutically acceptable formulati... Invention Ulk inhibitors and methods of use thereof. Described herein are compounds of formula (I) that are... P/S Pharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), gia... 2024 Invention Raf kinase inhibitors and methods of use thereof. Described herein are compounds that are RAF in... Invention Dual raf and tubulin inhibitors and methods of use thereof. Described herein are compounds that ... Invention Dual raf and tubulin inhibitors and methods of use thereof. Described herein are compounds of for... Invention Vps34 inhibitors and methods of use thereof. The present disclosure, in part, provide compounds ... Invention Vps34 inhibitors and methods of use thereof. The present disclosure, in part, provide compounds o... Invention Formulations of a csf-1r inhibitor. Described herein, in part, are pharmaceutically acceptable fo... Invention Formulations of a csf-1r inhibitor. Described herein, in part, are pharmaceutically acceptable f... Invention Formulations of vimseltinib. Described herein, in part, are pharmaceutically acceptable formulat... Invention Solid forms of an ulk inhibitor. Described herein, in part, are solid-state forms of the compoun... Invention Solid state forms of a kinase inhibitor. Described herein, in part, are solid-state forms of the ... Invention Methods of treating tenosynovial giant cell tumors. inter aliainter alia, methods of treating a t... P/S Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for use in... Invention Combination therapy for the treatment of mastocytosis. The present disclosure relates to the use... Invention Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-... Invention Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof. Described herein ar... Invention Methods of treating gastrointestinal stromal tumors. The present disclosure relates to methods of... Invention Gcn2 and perk kinase modulators and methods of use thereof. Described herein are compounds of for... Invention Combination therapy for the treatment of gastrointestinal stromal tumors. The present disclosure... Invention Gcn2 and perk kinase inhibitors and methods of use thereof. Described herein are compounds that ... 2023 Invention Methods of treating gastrointestinal stromal tumors with ripretinib. The present disclosure relat... Invention (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. Provided here... Invention Methods of treating melanoma with ripretinib. The present disclosure relates to methods of treat... Invention Methods of treating gastrointestinal stromal tumors. The present disclosure relates to methods o... Invention Amorphous kinase inhibitor formulations and methods of use thereof. Provided herein is an amorph... P/S pharmaceutical oncology treatments, namely, preparations for gastrointestinal stromal tumors, sys... Invention Methods of treating disorders with ulk inhibitors. Described herein are compounds that are inhib... Invention Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer. Describ... Invention Ulk inhibitors and methods of use thereof. Described herein are compounds that are inhibitors of... P/S Pharmaceutical oncology treatments, namely, preparations for gastrointestinal stromal tumors, sys... 2022 Invention Kit kinase inhibitors and methods of use thereof. Described herein are compounds that are inhibi... Invention Combination therapy using vps34 inhibitors. Described herein, in part, are methods of treating c... 2021 P/S Business administration of patient reimbursement programs; business administration of medication ... P/S pharmaceutical research and development providing medical information to patients relating to the... 2019 P/S Pharmaceutical oncology treatments, namely treatments for gastrointestinal stromal tumors, system... P/S Pharmaceutical oncology treatments, namely preparations for treating gastrointestinal stromal tum...